Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of iptacopan (LNP023) in PNH patients with active hemolysis
NCT03896152Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2019
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of Iptacopan in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Novartis. Started Apr 2019; status: completed.
02
Drugs
Iptacopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT03896152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03896152.